Tuesday, February 20, 2024

 palestine palestinian gaza ceasfire israel protest demonstration

From River To Sea Both Should Be Freed From Hatred And Suffering – OpEd

By 

In Arabic, the word Jihad is a noun meaning the activity of “striving and/or persevering.” According to Prophet Muhammad there are two types of Jihad: minor and major. Once when Muslims were returning from a military expedition, which for Prophet Muhammad was a minor jihad. He said to the fighters that now they had to go through the major jihad. When Prophet Muhammad was asked what he meant by major jihad, he said it was the spiritual jihad. 

On another occasion, he said the real mujahid is the one who declares jihad against his/her carnal soul. (Tirmidhi). Exercising self-control and using willpower and reason to overcome one’s anger is described by Prophet Muhammad as “the major jihad.” Overcoming our own feelings of hatred, revenge and anger is much more difficult than overcoming our enemies.

In today’s world of fanaticism and extremism the words of Al-Ghazali, a 12th century Persian Muslim theologian, need to be repeated by all the world’s religious and political leaders: “Declare your jihad on thirteen enemies you cannot see – Egoism, Arrogance, Conceit, Selfishness, Greed, Lust, Intolerance, Anger, Lying, Cheating, Gossiping and Slandering. If you can master and destroy them, then you will be ready to fight the enemy you can see.”

Congresswoman Rashida Tlaib says, “From the river to the sea is an aspirational call for freedom, human rights, and peaceful coexistence, not death, destruction, or hate.” I say we can make it truly aspirational by making it focus on both people first and the land second. “From the river to the sea Palestinians and Israelis should be freed of hatred and suffering by ‘a two state for two peoples sharing of the land peacefully.'”

But the Hamas’ 2017 charter states that in principle, it “rejects any alternative to the full and complete liberation of Palestine, from the river to the sea.” Hamas opposes a two state solution, wants all the land between the Mediterranean Sea and the River Jordan, and violently opposed the Oslo peace accords negotiated by Israel and the Palestine Liberation Organization (PLO) in the mid-1990s. If the war ends with Hamas eliminated, and with a new Israeli government elected; there is the hope that the miracle of the Yom Kippur War may be repeated. 

On October 27, 1978, only five years after Egypt started the Yom Kippur War with a surprise  attack on Israel, Egyptian President Anwar Sadat and Israeli Prime Minister Menachem Begin were named winners of the Nobel Peace Prize for their progress toward achieving a Middle East accord. The Yom Kippur War was followed six years later by a Peace Treaty between Egypt and Israel. 

Could the same process follow the defeat of Hamas, and its opposition to a two state solution?  The only possible chance for avoiding more wars is the two state solution. To establish a Palestinian state alongside Israel. That will not be possible with the current leaders on either side. Extremists, both Israeli and Palestinian, will do all they can to sink the idea, as they have done since the 1990s. If this war does not deliver enough of a shock to break deeply-held prejudices and to make the idea of two states viable, nothing will. And without a mutually-acceptable way of ending the conflict, more generations of Palestinians and Israelis will be sentenced to more wars.

Although it might seem impossible now, I do believe that within a decade or two Muslims will visit Jerusalem and pray together with Jews as Prophet Isaiah states: “In that day there will be a highway from Egypt to Assyria. The Assyrians will go to Egypt, and the Egyptians to Assyria. The Egyptians and Assyrians will worship together. On that day Israel  will join a three-party  alliance with Egypt and Assyria, a blessing upon the heart. The LORD of Hosts will bless them saying, “Blessed be Egypt My people, Assyria My handiwork, and Israel My inheritance.” …(Isaiah 19:23-5) And then “Nation shall not lift sword against nation, neither shall they learn war anymore. (Isaiah 2:4)

For more than seven decades political nationalist leaders in Israel and Palestine have failed to find a way to end the conflict between their two peoples. Perhaps it is time for religious leaders who understand the religious importance of repentance, humility, forgiveness, compromise and hope for peace in overcoming more than seven decades of pain and anger. As the Qur’an states: “Perhaps Allah will put, between you and those to whom you have been enemies among them, affection. And Allah is competent, and Allah is Forgiving and Merciful.”  (60:7) Then the words of the Qur’an will be full-filled “From the depths of Darkness into the Light; for Allah is very kind and merciful to you.” (Qur’an 57:9)

There is much about the Gaza war that we still don’t know: how long it will last, what the death toll will be, how many hostages can be rescued or returned, and how successful Israel will be in its declared objective of destroying Hamas.

But so far the most important fact is that Iran isn’t getting what it wanted from the war. The real goal was to disrupt the gradual deepening of the strategic ties between Israel and its most important Arab neighbors. Tehran’s support for Bashar al-Assad in Syria is responsible for many times more deaths and refugees than all the Israeli-Palestinian wars combined. Indeed, Iran’s supreme leader Ayatollah Ali Khamenei told Hamas leader Ismail Haniyeh that Iran would not enter Hamas’ war with Israel; and accused the terror group of not giving Iran any prior warning of the October 7 attacks.

Dr. Mohamed Chtatou, a Professor at a university in Rabat, Morocco writes: “After the current (Hamas-Israel) war, Israel’s ultra-nationalist coalition will undoubtedly be undermined by public opinion, and probably by a commission of inquiry. If the Palestinian Authority were to agree to take over Gaza – backed by the international reconstruction aid that would inevitably arrive – and if a centrist coalition government were to emerge in Israel, everything would once again be possible. Two difficult “ifs”? Perhaps, but there is no serious alternative.”

The Qur’an refers to Prophet Abraham as a community or a nation: “Abraham was a nation/community [Ummah]; dutiful to God, a monotheist [hanif], not one of the polytheists.” (16:120) If Prophet Abraham is an Ummah; then fighting between the descendants of Prophets Ishmael and Isaac is a civil war and should always be avoided. And prior to the 20th century Arabs and Jews never did make war with each other. Even the surprise attack by Egypt and Syria of the Yom Kippur War was followed six years later by a Peace Treaty between Egypt and Israel. Could the same process follow the defeat of Hamas?

If all Arabs and Jews can live up to the ideal that ‘the descendants of Abraham’s sons should never make war against each other’ is the will of God; we will help fulfill the 2700 year old vision of Prophet Isaiah: “In that day there will be a highway from Egypt to Assyria. The Assyrians will go to Egypt, and the Egyptians to Assyria. The Egyptians and Assyrians will worship together. In that day Israel  will join a three-party alliance with Egypt and Assyria, a blessing upon the heart. The LORD of Hosts will bless them saying, “Blessed be Egypt My people, Assyria My handiwork, and Israel My inheritance.”…(Isaiah 19:23-5)

Prophet Muhammad said: “Should I not tell you what is better in degree than prayer, fasting, and charity.” They (the companions) said: “Yes.” He said: “Reconciling people, because grudges and disputes are a razor (that shaves off faith).” (Ahmad, Abu Dawood, and At-Tirmithi)

This is an excellent guide to dealing with the three-generation old Israeli-Palestinian conflict. Rather than focusing mostly on what the other side did to us, we all should focus on how the conflict has hurt all of us, and how much better our future would be if we could live next to each other in peace. If the descendants of Prophet Isaac and Prophet Ishmael negotiate a settlement that reflects the religious policy that “…there is no sin upon them if they make terms of settlement between them – and settlement [reconciliation and peace] is best.” (Quran 4: 128)  

Three thousand Hamas gunmen invaded southern Israel on October 7 2023, killing 1,200 people and taking another 253 back to Gaza as hostages. As of February 19, 2024, 30,000 Palestinians, including about 12,000 Hamas fighters killed in Gaza since Israel launched a major military campaign in response. 

If Hezbollah attacks Israel there will be two to three times more deaths. A Hamas official based in Qatar told Reuters that the terror group estimated it had lost 6,000 fighters during the four-month-old conflict, well below the 12,000 Israel says it has killed. The comments were a rare acknowledgment from the Hamas terror group that it has suffered significant losses and appeared to mark the first time that Hamas has differentiated between combatants and civilians in a death toll from the war.

Iran has warned its proxy Hezbollah not to give Israel cause to launch a full-scale war along the Israel-Lebanon border, fearing it would risk gains it believes Iran has made in the region since Hamas’s October 7 massacres in southern Israel.

The Nakba (catastrophe), the displacement of Palestinians during the 1948 establishment of the State of Israel and the War of Independence, could have been avoided if the Palestinian leadership had accepted the UN two state solution. Indeed, if the Palestinian leadership had accepted the British 1937 two state solution; millions of Jews would have been able to escape the Holocaust (catastrophe). Hopefully, the Palestinians will not make an all or nothing mistake again. 

A mid February national poll by Channel 12 news indicated that the current opposition, along with Benny Gantz’s National Unity party (previously in the opposition but now a member of the emergency government), could secure 75 of the Knesset’s 120 seats if elections were held today, with the bloc loyal to Prime Minister Netanyahu far behind at 45. Israel will be ready for a two state solution if the Palestinians desire an honest peace, meaning a total Peace to end the 83 years of conflict. 



Rabbi Allen S. Maller
Allen Maller retired in 2006 after 39 years as Rabbi of Temple Akiba in Culver City, Calif. He is the author of an introduction to Jewish mysticism. God. Sex and Kabbalah and editor of the Tikun series of High Holy Day prayerbooks.
Alberta government declares ‘early start’ to wildfire season


Connor O'DonovanVideo Journalist, Alberta Bureau
Published on Feb. 20, 2024, 

After the destructive wildfires in Canada in 2023, Alberta is getting a head start on preparations this year by declaring an 'early start' to the season

Alberta had a record wildfire year, what 2024 could hold for the province


Visit The Weather Network's wildfire hub to keep up with the latest on the 2024 wildfire season across Canada.

Alberta’s forestry minister has declared an "early start to wildfire season," announcing a number of new measures aimed at preparing for a potentially severe year.

“We have requested funding for an additional 100 wildland firefighters in budget 2024,” Todd Loewen, forestry minister, said Tuesday afternoon at a warehouse in Whitecourt, Alta.

RELATED: Alberta has dozens of wildfires still burning this winter. Here's why

“As of today, a permit is required for any burning planned in the forest protection area. This will reduce the likelihood of new, human-caused wildfires.”
(Alberta government/YouTube)

Alberta Wildfire typically defines the season as March through October. Loewen, though, says prevailing conditions are motivating the province to take a proactive stance, and it asked Albertans to do the same.

“We know we’re in an El NiƱo right now that’s been causing us to have warmer and drier temperatures overall. We’re hoping that comes to an end,” Loewen said.

“I urge Albertans, especially those who live in or near the forest protection areas, to become familiar with FireSmart principles and prepare their homes, properties and communities accordingly.”



Loewen stated thermal-imaging drones will be used to monitor fires following a pilot project in 2023, and nighttime helicopter operations will be expanded.

The forestry minister noted the 100 new positions would result in 1,000 firefighting personnel working by May 15.

Alberta is scheduled to release its 2024 budget next week.

 

Researchers are using RNA in a new approach to fight HIV


You know mRNA, now meet siRNA

Peer-Reviewed Publication

UNIVERSITY OF WATERLOO




Society learned about the value of mRNA during the COVID-19 pandemic when we saw scientists and medical professionals harness its power to deliver a vaccine for the virus within a year.

Now, University of Waterloo pharmacy associate professor Emmanuel Ho has developed a novel nanomedicine loaded with genetic material called small interfering RNAs (siRNA) to fight human immunodeficiency virus (HIV) using gene therapy. These siRNAs regulate which genes or proteins are turned on or off in our cells and showed a 73 per cent reduction in HIV replication.

“This opens the door for new therapeutics in the fight against HIV,” said Dr. Ho, who is among Waterloo’s researchers and entrepreneurs leading health innovation in Canada.

Autophagy, also known as the body’s recycling process, plays an important role in our body to eliminate microbes such as viruses and bacteria inside cells. HIV is quite smart and produces a protein, Nef, that prevents cells from activating autophagy.

This is the first research to develop a combination nanomedicine that can reactivate autophagy and prevent HIV entry into cells, allowing our body to re-initiate its defence system.

Additionally, HIV has a gene, CCR5, that allows the virus to enter a cell. The siRNAs target both Nef and CCR5 to reduce HIV infection. 

This nanomedicine is intended to be applied vaginally to protect against sexual transmission of HIV. As a result, the nanomedicine is designed to be stable without leakage of siRNAs in the acidic vaginal environment but release the siRNA once inside cells.

“Viruses are smart. They produce Nef proteins to prevent autophagy from occurring,” Ho said. “Our process allows our body to fight the viral infection without needing additional drugs,” 

Ho confirms that the next steps include further optimizing the process and improving our understanding of how autophagy plays a role in how our cells protect us from viruses.

“We also hope this will shed some light to develop more alternative approaches to effectively reduce antimicrobial resistance,” Ho said.

The study, pH-sensitive dual-preventive siRNA-based nanomicrobicide reactivates autophagy and inhibits HIV infection in vaginal CD4+ cells, was recently published in the Journal of Controlled Release.

 

Annual breast cancer screening beginning at 40 saves lives


Peer-Reviewed Publication

RADIOLOGICAL SOCIETY OF NORTH AMERICA




OAK BROOK, Ill. – Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks, according to a new study published today in Radiology, a journal of the Radiological Society of North America (RSNA).

Breast cancer is the second most common cause of cancer death for women in the U.S. Despite research demonstrating that consistent participation in screening mammography can reduce breast cancer deaths by 40%, only 50% or less of eligible women actually participate in annual screening.

“There is an ongoing debate over the recommendations for breast cancer screening, specifically about when to start and the frequency of screening,” said lead researcher Debra L. Monticciolo, M.D., professor of radiology at Dartmouth Geisel School of Medicine in Hanover, New Hampshire.

Dr. Monticciolo said a recommendation by the U.S. Preventive Services Task Force (USPSTF) in 2009 to screen every other year, or biennially, beginning at age 50 resulted in a nationwide decline in screening participation. The USPSTF drafted new recommendations in 2023, suggesting women participate in biennial screening between 40 and 74. The American College of Radiology, the Society of Breast Imaging and the National Comprehensive Cancer Network recommend annual screening for women at average risk for breast cancer beginning at age 40 and continuing as long as the woman is in good health.

In the study, Dr. Monticciolo and colleagues performed a secondary analysis of Cancer Intervention and Surveillance Modeling Network (CISNET) 2023 median estimates of breast cancer screening outcomes. CISNET modeling data gives researchers the opportunity to estimate the outcomes of screening at various frequencies and starting ages using U.S. data.

The researchers compared the benefits of screening, including mortality reduction, life years gained, breast cancer deaths averted, and its risks—including benign, or unnecessary, biopsies and recall rates—for four different scenarios: biennial screening of women 50-74 (the longstanding USPSTF recommendation), biennial screening of women 40-74 (the task force’s new draft recommendation), annual screening 40-74, and annual screening 40-79. CISNET does not offer modeling past age 79.

The review of CISNET estimates showed that annual screening of women 40-79 with either digital mammography or tomosynthesis showed a mortality reduction of 41.7%. Biennial screening of women 50-74 and 40-74 showed mortality reduction of 25.4% and 30%, respectively. Annual screening of women 40-79 years showed the lowest per mammogram false-positive screens (6.5%) and benign biopsies (0.88%) compared to other screening scenarios.

“The biggest takeaway point of our study is that annual screening beginning at 40 and continuing to at least age 79 gives the highest mortality reduction, the most cancer deaths averted, and the most years of life gained,” Dr. Monticciolo said. “There’s a huge benefit to screening annually until at least 79 and even more benefit if women are screened past 79.”

Dr. Monticciolo said that although the USPSTF uses CISNET modeling to formulate its recommendations, it refers to recall rates and benign biopsies as harms, rather than risks.

“To balance the harms and benefits of screening mammography, they’re willing to give up some mortality benefit to avoid women being recalled for additional imaging and benign biopsies,” she said. 

According to the researchers’ analyses, the chance of a woman having a benign biopsy following annual screening is less than 1%, and all recall rates for screening mammography are under 10%. When screening is performed annually with tomosynthesis, the recall rate decreases to 6.5%.

“The risks of screening are non-lethal and manageable for most women,” she said. “But advanced breast cancer is often lethal. Breast cancer is easier to treat if it’s found earlier; we’re able to spare women extra surgeries and chemotherapy. It’s just a better idea to shift to early detection, and that’s what screening does.”

Dr. Monticciolo said she hopes that her study will add to the body of literature that supports annual screening beginning at age 40 as the best way to diagnose cancer early.

“This paper is important because it shows once again that there’s a tremendous increase in mortality benefit by screening annually between the ages of 40-79, and that the chances of experiencing harm are low on a per-exam basis,” she said. “It comes down to valuing women’s lives. I am hoping that primary care physicians see that risks of screening are manageable, and the benefits are tremendous. We need to do this for women.”

###

“Outcomes of Breast Cancer Screening Strategies Based on Cancer Intervention and Surveillance Modeling Network Estimates.” Collaborating with Dr. Monticciolo were R. Edward Hendrick, Ph.D., and Mark A. Helvie, M.D.

Radiology is edited by Linda Moy, M.D., New York University, New York, N.Y., and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on breast cancer screening, visit RadiologyInfo.org.

 

Bar-Ilan University researchers produce “laboratory testicles”


The artificial testicles will contribute to the advancement of research in male fertility and sexual development disorders, and are expected to facilitate the eventual production of sperm in the laboratory


Peer-Reviewed Publication

BAR-ILAN UNIVERSITY

Embryonic testis organoids bright field 

IMAGE: 

A BRIGHT FIELD IMAGE OF A TESTICULAR ORGANOID CREATED FROM MOUSE EMBRYOS AND INCUBATED IN A DISH FOR 14 DAYS. THE TUBULAR STRUCTURES FORMED IN THE DISH ARE CLEARLY VISIBLE. 

 

 

 

view more 

CREDIT: CHELI LEV




The testis is responsible for sperm production and testosterone synthesis. Abnormalities in testis development and function lead to disorders of sex development (DSD) and male infertility. Currently, no in vitro system exists for modeling the testis.

 

Dr. Nitzan Gonen, a researcher specializing in the process of fetal sex determination, together with research students Aviya Stopel, Cheli Lev and Stav Dahari, has succeeded in creating "laboratory testicles" that may significantly advance understanding of the mechanisms involved in sex determination and provide solutions for male infertility, which affects one in 12 men worldwide.

 

The artificial testicles produced in Dr. Gonen’s lab at the Goodman Faculty of Life Sciences and the Institute of Nanotechnology and Advanced Materials at Bar-Ilan University, are testis organoids – tiny, artificial organs produced from real mouse testis. Development of organoids has greatly advanced in the last decade with the realization that two-dimensional cellular sample in vitro cannot mimic the behavior of an entire organ. Today, organoids of the brain, kidneys, intestines, and other organs have already been produced. The testicular organoids created by Gonen's group closely simulate a natural testicle.

 

The artificial testicles were cultured from immature testicular cells sampled from neonatal mice. The research team realized the procedure was a success when they identified tubule-like structures and cellular organization highly resembling that of the in vivo testis. These tubular structures parallel the multiple seminiferous tubules present in the natural testicle, where the sperm is produced.

 

The organoids were successfully cultured in vitro for nine weeks. This is considered a long period of time and can, theoretically, be enough time to complete the process of sperm production and hormone secretion. In mice this takes 34 days, so the relatively long lifespan of the organoids may allow these processes to occur in vitro. Dr. Gonen doesn’t yet know if the existing model will actually produce sperm cells, but the laboratory team has already noticed signs of the beginning of meiosis, a process in which gametes are produced. Gametes are reproductive cells, in this case sperm cells with half the number of chromosomes as in a normal cell, that "await" for the completion of the other half from another gamete, in this case an egg, upon fertilization.

 

Organoids usually resemble organs in the embryonic stage. In this case the researchers created conditions that allowed the organoid to mature in the laboratory and showed that even testicles grown from embryonic cells can develop and grow clear sperm tubes. The team was unsuccessful in its attempt to grow organoids from adult mice testis.

 

“Artificial testicles are a promising model for basic research on testicle development and function, which can be translated into therapeutic applications for disorders of sexual development and infertility,” explains Dr. Gonen. In the future she plans to produce organoids using human samples. A testis produced from human cells, for example, could help children being treated for cancer, which may impair their ability to produce functional sperm. As children are too young to produce their own sperm, these samples can be frozen and used in the future to have children. Gonen’s vision is to grow testes organoids from biopsies of children with cancer and hopefully grow fertile sperm in vitro.  

 

The finding of this study were recently published in the International Journal of Biological Sciences.

 SIXTY YEARS LATER....

Salk scientists discover new target for reversible, non-hormonal male birth control


Oral administration of HDAC inhibitor blocked sperm production and fertility in mice without affecting libido


Peer-Reviewed Publication

SALK INSTITUTE

Authors 

IMAGE: 

FROM LEFT: RUTH YU, SUK-HYUN HONG, RONALD EVANS, ANNETTE ATKINS, AND MICHAEL DOWNES

view more 

CREDIT: SALK INSTITUTE




LA JOLLA (February 20, 2024)—Surveys show most men in the United States are interested in using male contraceptives, yet their options remain limited to unreliable condoms or invasive vasectomies. Recent attempts to develop drugs that block sperm production, maturation, or fertilization have had limited success, providing incomplete protection or severe side effects. New approaches to male contraception are needed, but because sperm development is so complex, researchers have struggled to identify parts of the process that can be safely and effectively tinkered with. 

Now, scientists at the Salk Institute have found a new method of interrupting sperm production, which is both non-hormonal and reversible. The study, published in Proceedings of the National Academy of Sciences (PNAS) on February 20, 2024, implicates a new protein complex in regulating gene expression during sperm production. The researchers demonstrate that treating male mice with an existing class of drugs, called HDAC (histone deacetylase) inhibitors, can interrupt the function of this protein complex and block fertility without affecting libido. 

“Most experimental male birth control drugs use a hammer approach to blocking sperm production, but ours is much more subtle,” says senior author Ronald Evans, professor, director of the Gene Expression Laboratory, and March of Dimes Chair in Molecular and Developmental Biology at Salk. “This makes it a promising therapeutic approach, which we hope to see in development for human clinical trials soon.”

The human body produces several million new sperm per day. To do this, sperm stem cells in the testes continuously make more of themselves, until a signal tells them it’s time to turn into sperm—a process called spermatogenesis. This signal comes in the form of retinoic acid, a product of vitamin A. Pulses of retinoic acid bind to retinoic acid receptors in the cells, and when the system is aligned just right, this initiates a complex genetic program that turns the stem cells into mature sperm.

Salk scientists found that for this to work, retinoic acid receptors must bind with a protein called SMRT (silencing mediator of retinoid and thyroid hormone receptors). SMRT then recruits HDACs, and this complex of proteins goes on to synchronize the expression of genes that produce sperm.

Previous groups have tried to stop sperm production by directly blocking retinoic acid or its receptor. But retinoic acid is important to multiple organ systems, so interrupting it throughout the body can lead to various side effects—a reason many previous studies and trials have failed to produce a viable drug. Evans and his colleagues instead asked whether they could modulate one of the molecules downstream of retinoic acid to produce a more targeted effect. 

The researchers first looked at a line of genetically engineered mice that had previously been developed in the lab, in which the SMRT protein was mutated and could no longer bind to retinoic acid receptors. Without this SMRT-retinoic acid receptor interaction, the mice were not able to produce mature sperm. However, they displayed normal testosterone levels and mounting behavior, indicating that their desire to mate was not affected. 

To see whether they could replicate these genetic results with pharmacological intervention, the researchers treated normal mice with MS-275, an oral HDAC inhibitor with FDA breakthrough status. By blocking the activity of the SMRT-retinoic acid receptor-HDAC complex, the drug successfully stopped sperm production without producing obvious side effects. 

Another remarkable thing also happened once the treatment was stopped: Within 60 days of going off the pill, the animals’ fertility was completely restored, and all subsequent offspring were developmentally healthy.

The authors say their strategy of inhibiting molecules downstream of retinoic acid is key to achieving this reversibility.  

Think of retinoic acid and the sperm-producing genes as two dancers in a waltz. Their rhythm and steps need to be coordinated with each other for the dance to work. But if you throw something in that makes the genes miss a step, the two are suddenly out of sync and the dance falls apart. In this case, the HDAC inhibitor causes the genes’ misstep, halting the dance of sperm production. 

However, if the dancer can find its footing and get back in step with its partner, the waltz can resume. In the same way, the authors say that removing the HDAC inhibitor allows the sperm-producing genes to get back in sync with the pulses of retinoic acid, turning sperm production back on as desired. 

“It’s all about timing,” says co-author Michael Downes, a senior staff scientist in Evans’ lab. “When we add the drug, the stem cells fall out of sync with the pulses of retinoic acid, and sperm production is halted, but as soon as we take the drug away, the stem cells can reestablish their coordination with retinoic acid and sperm production will start up again.”

The authors say the drug doesn’t damage the sperm stem cells or their genomic integrity. While the drug was present, the sperm stem cells simply continued regenerating as stem cells, and when the drug was later removed, the cells could regain their ability to differentiate into mature sperm.

“We weren’t necessarily looking to develop male contraceptives when we discovered SMRT and generated this mouse line, but when we saw that their fertility was interrupted, we were able to follow the science and discover a potential therapeutic,” says first author Suk-Hyun Hong, a staff researcher in Evans’ lab. “It’s a great example of how Salk’s foundational biological research can lead to major translational impact.”

Other authors include Glenda Castro, Dan Wang, Russell Nofsinger, Annette R. Atkins, and Ruth T. Yu of Salk, Maureen Kane, Alexandra Folias, and Joseph L. Napoli of UC Berkeley, Paolo Sassone-Corsi of UC Irvine, Dirk G. de Rooij of Utrecht University, and Christopher Liddle of the University of Sydney.

The work was supported by the National Institutes of Health (grants CA265762 and CA220468) and the Next Generation Sequencing and Flow Cytometry Cores at Salk, funded by the Salk Cancer Center (NCI grant NIH-NCI CCSG: P30 014195).

About the Salk Institute for Biological Studies:

Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge. Learn more at www.salk.edu.


Generating 'buzz' about new products can influence their success


 NEWS RELEASE 

BINGHAMTON UNIVERSITY

Barbenheimer 

IMAGE: 

PREANNOUNCEMENT MARKETING CAN OFTEN INFLUENCE A PRODUCT’S SUCCESS, AS IN THE CASE OF THE FILMS "BARBIE" AND "OPPENHEIMER," RESULTING IN THE BARBENHEIMER PHENOMENON.

 

view more 

CREDIT: BINGHAMTON UNIVERSITY, STATE UNIVERSITY OF NEW YORK; UNIVERSAL; WARNER BROTHERS



BINGHAMTON, N.Y. -- The way companies announce new products or build up hype can often influence their success once those new products hit the market, according to new research from Binghamton University, State University of New York. Whether it's an upcoming blockbuster movie or a new rollout from major companies like Coca-Cola or Apple, the new research shows how companies might use this type of preannouncement marketing to their advantage.

How often have you watched trailers for an upcoming movie and thought, “I can’t wait to see that,” when it hits theaters next year?

It’s no surprise when critically acclaimed movies score well at the box office, but when films like “Barbie” or “Oppenheimer” go above and beyond that, the extra push can often be traced back to the buzz they generated building up to their debut on the big screen.

Preannouncement marketing can often influence a product’s success, whether it’s an upcoming blockbuster movie or a new product rollout from major companies like Coca-Cola or Apple. A research study from Binghamton University’s School of Management Associate Professor Debi Mishra shows how companies might use this type of marketing to their advantage.

What these communications provide is another way to think about shareholder return because shareholders want the money that they’re putting in to appreciate in value, said Mishra, a marketing expert who conducted the study. While that often depends on the actual product performance, he said, how companies manage and communicate the “buzz” plays a big role.

“New products are the heartbeat of a company, especially those products that are more consumer-facing, so how a company communicates with consumers or stakeholders about new products is the key to future growth and survival,” Mishra said. “Do you provide all the information upfront or more toward the preannouncement phase? And depending on how this information is communicated, they create surprise in the marketplace that can prove beneficial.”

Mishra and a fellow researcher gauged the impact by collecting data from 149 product launch events and their preceding preannouncements, as reported in The Wall Street Journal from 2005–2018.

By examining what kind of information came out within one year preceding a product’s announcement, whether it was a costly announcement (the company loses money if it doesn’t introduce the product) or a costless one, the researchers could compare the effect on stock across these scenarios.

They found that costless approaches generally resulted in a positive stock market reaction, and contrary to expectations, losses from not investing as much up-front in building up product hype could be compensated after the release. Alternatively, costly approaches didn’t often result in a significant stock market reaction either way.

Examples included:

  • The announcement of one new beverage by Coca-Cola didn’t promise when it would be rolled out or how much the company had invested in the new product, meaning it could’ve been easy for the company to reverse that announcement if needed.
  • An announcement by IBM to use artificial intelligence to draw insights from digital data and create graphics of data that, while positive, stated it was part of the company’s $1 billion investment.

“If companies create all this buzz about a product but never release it, they might benefit from the stock market having gone up initially, but shareholders will suffer down the road,” Mishra said. “It also makes a difference whether the company makes any kind of guarantee, such as purchasing land worth $20 million for a factory to make the new product. That’s a credible commitment because that money could be lost if they never introduce that product. The market is smart enough to figure these types of things out.”

Mishra said the research also showed a “surprise effect” can impact the market’s reaction to new products.

If a company makes a new product announcement and has already put in a lot of visible commitment behind it, that is no longer a surprise to the market because of an implied expectation the company would follow through with the introduction.

Mishra said a company’s new product announcement that doesn’t provide upfront information about how much is being invested into it could potentially make a larger splash on the market once it comes out.

“If you have something really cool to put out – Brad Pitt is starring in some big upcoming movie – you can’t keep it under wraps all the time, but if your intention is truly honest about introducing that product or movie, it still could be a good idea to keep things somewhat secretive,” Mishra said. “All of a sudden, you’re in the position to have your audience or the market react by saying, ‘Oh, we didn’t expect that!”

The study, "Does the economic value of new product announcements depend upon preannouncement signals? An empirical test of information asymmetry theories," was published in the Journal of Product & Brand Management.